Genitourinary Collaboration and Licensing Deals 2016-2023

$3,995.00

Genitourinary Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023

Publication date
October 2023
Number of pages
150+
Product type
Research report
Available formats
PDF document
Report edition
4
SKU
CP2208

Genitourinary Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genitourinary deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of genitourinary deals from 2016 to 2023.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of genitourinary dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in genitourinary dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the genitourinary field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in genitourinary dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of genitourinary deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of genitourinary deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in genitourinary deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Key benefits

Genitourinary Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse genitourinary collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

 

Report scope

Genitourinary Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of genitourinary trends and structure of deals entered into by leading biopharma companies worldwide.

Genitourinary Collaboration and Licensing Deals includes:

  • Trends in genitourinary dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of genitourinary deal records covering pharmaceutical and biotechnology
  • The leading genitourinary deals by value
  • Most active genitourinary licensing dealmakers

In Genitourinary Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Genitourinary Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Genitourinary Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse genitourinary collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in genitourinary dealmaking

 

2.1. Introduction

2.2. Genitourinary partnering over the years     

2.3. Genitourinary partnering by deal type

2.4. Genitourinary partnering by industry sector

2.5. Genitourinary partnering by stage of development

2.6. Genitourinary partnering by technology type

2.7. Genitourinary partnering by therapeutic indication

 

Chapter 3 – Financial deal terms for genitourinary partnering

 

3.1. Introduction

3.2. Disclosed financials terms for genitourinary partnering

3.3. Genitourinary partnering headline values

3.4. Genitourinary deal upfront payments

3.5. Genitourinary deal milestone payments

3.6. Genitourinary royalty rates

 

Chapter 4 – Leading genitourinary deals and dealmakers

 

4.1. Introduction

4.2. Most active in genitourinary partnering

4.3. List of most active dealmakers in genitourinary    

4.4. Top genitourinary deals by value

 

Chapter 5 – Genitourinary contract document directory

                                            

5.1. Introduction

5.2. Genitourinary partnering deals where contract document available

 

Chapter 6 – Genitourinary dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by genitourinary therapeutic target

 

Deal directory

 

Deal directory – Genitourinary deals by company A-Z 2016 to 2023

Deal directory – Genitourinary deals by technology type 2016 to 2023

 

Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

 

Table of figures

 

Figure 1: Genitourinary partnering since 2016

Figure 2: Genitourinary partnering by deal type since 2016

Figure 3: Genitourinary partnering by industry sector since 2016

Figure 4: Genitourinary partnering by stage of development since 2016

Figure 5: Genitourinary partnering by technology type since 2016

Figure 6: Genitourinary partnering by indication since 2016

Figure 7: Genitourinary deals with a headline value

Figure 8: Genitourinary deals with upfront payment values

Figure 9: Genitourinary deals with milestone payment

Figure 10: Genitourinary deals with royalty rates

Figure 11: Active genitourinary dealmaking activity since 2016

Figure 12: Top genitourinary deals by value since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

Abbott Laboratories, Abbvie, Acer Therapeutics, Acerus, Acurx Pharmaceuticals, AdaptivEndo, Advanz Pharma, Akebia Therapeutics, Albert Einstein College of Medicine, Alio Medical, AliveCor, Alivio Therapeutics, Allecra Therapeutics, Allergan, Alnylam Pharmaceuticals, Altasciences, Altavant Sciences, AM-Pharma, American Lung Association, American Renal Associates, American Urological Association, Amerigen Pharmaceuticals, Amgen, Ampio Pharmaceuticals, Angion Biomedica, Antares Pharma, Anteris Bio, Anthem, Apellis Pharmaceuticals, Aquestive Therapeutics, Aquinox Pharmaceuticals, Arch Biopartners, Ardelyx, Arena Pharmaceuticals, Arrevus, Ascend Clinical, Asieris Pharmaceuticals, ASKA Pharmaceuticals, Aspect Biosystems, Astellas Pharma, AstraZeneca, Astute Medical, Aurinia Pharmaceuticals, AWAK Technologies, Aziyo Biologics, Baxter International, Baylor Health Care System, Beacon Discovery, BenevolentAI, Beth Israel Deaconess Medical Center, Biim Ultrasound, Bio-Techne, BIOASTER, Biomedical Advanced Research and Development Authority, bioMerieux, Blue Cross Blue Shield Association, Blue Water Biotech, Boehringer Ingelheim, Bridge Medicines, Brigham and Women's Hospital, BrightInsight, Caelum Biosciences, Caldera Pharmaceuticals, Calliditas Therapeutics, Cantex Pharmaceuticals, Cara Therapeutics, CARB-X, Cardio Renal Society of America, CareDx, CB2 Therapeutics, CELLINK, Centogene, ChemoCentryx, China Medical System, Chinook Therapeutics, Cigna Healthcare, CJ Corp, Cleveland Clinic, Clinical Laserthermia Systems (CLS), CloudCath, Cogentix Medical, Columbia University, Cook Biotech, Corino Therapeutics, Creative Medical Technologies, Cricket Health, Danish Innovation Fund, Datavant, Debiopharm, Defense Threat Reduction Agency, DemeTECH, Dicerna Pharmaceuticals, DILIsym Services, Dimerix Biosciences, Diurnal, Drexel University, Duchesnay, Ecole Polytechnique Federale de Lausanne, eGenesis, EirGen Pharma, Eledon Pharmaceuticals, Elexopharm, Eliaz Therapeutics, Eli Lilly, Enteris Biopharma, Enzyvant Science, Epigen Biosciences, Erasmus University Medical Center, Erlangen University Hospital, Eton Pharmaceuticals, Eurofins Scientific, Everest Medicines, Evestra, Evotec, Ferring Pharmaceuticals, Fimbrion Therapeutics, FirstString Research, Forendo Pharma, Fortress Biotech, Fosun Pharmaceutical, Foundation for International Urogynecological Assistance, Frazier Healthcare Ventures, Frenova Renal Research, Fresenius, Fresenius Kabi Pharmaceuticals, Fresenius Medical Care, Fuji Yakuhin, Gedeon Richter, Geisinger Medical Center, Genewiz, Genexo, Gilead Sciences, Goldfinch Bio, GSK, Hangzhou Zhongmei Huadong Pharmaceutical, Harvard Stem Cell Institute, Harvard University, Health Logic Interactive, Helix BioPharma, HemoCleanse, HHS Technology Group, HIBio, Horizon Therapeutics, Humana, HydroCision, Hyloris Pharmaceuticals, Ibidi, Icahn School of Medicine at Mount Sinai, Ideal Medical Solutions, IGAN Biosciences, Ilias Biologics, Immedica, ImpediMed, Innovation Network Corporation, Innovus Pharmaceuticals, IntelGenx, IntrinsiQ, Inventia Healthcare, Invitae, InVivo, Ion Channel Innovations, Ionis Pharmaceuticals, Itochu, Jana Care, Janssen Pharmaceuticals, Janssen Research & Development, Japan Tobacco, Johns Hopkins University, JSR, Juventas Therapeutics, Kahn-Sagol-Maccabi, Kaken Pharmaceutical, Karolinska Institute, KBI BioPharma, Keryx Biopharmaceuticals, Kumamoto University, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Kyowa Hakko Kogyo, Laborie Medical Technologies, Lavasta Pharma, Leiden University, Lifeline Vascular Care, Locus Biosciences, Luqa Pharmaceuticals, Massachusetts General Hospital, Mathematica, Mayo Clinic, MediBeacon, Medice Arzneimittel Pütter, MedImmune, Medinova, Medipal Holdings, Medison Pharma, Melinta Therapeutics, Memorial Sloan Kettering Cancer Center, Menarini, Merck Sharpe & Dohme, Merz, Mesh Bio, Metabolon, MetaSight Diagnostics, Methuselah Foundation, Michigan Medicine, MicrobeDx, Mironid, Mitobridge, Morehouse School of Medicine, MorphoSys, Mount Sinai Health System, MultiOmic Health, Murdoch Childrens Research Institute, Myovant Sciences, NanoVibronix, Nantes University, Nashville Biosciences, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, National Institutes of Health Clinical Center, National Kidney Foundation, National Research Council Canada, NCPC GeneTech, Neokidney, Nephria Bio, Neptune Technologies & Bioressources, Nestle Health Science, NeuralStem, Nicoya, NMI Natural and Medical Sciences Institute, Nosopharm, Novartis, Novo Nordisk, Numares, OmniVision Technologies, Onegevity, OpGen, OPKO Health, Organovo, OrsoBio, OSE Immunotherapeutics, Otsuka, Outpost Medicine, Palette Life Sciences, Panion & BF Biotech, Par Pharmaceutical, Patheon N.V., Pharmacological research Institute Mario Negri, Pherecydes Pharma, Pierre Fabre, Pivotal bioVenture Partners, PPD, Precision Image Analysis, Procept BioRobotics, Promepla, Promethera Biosciences, Prometic Life Sciences, Proteomics International, Purdue Pharma, PureTech Health, PX Therapeutics, Pythagoras Medical, Quebec Urological Association Foundation, Quimica Europea, Reata Pharmaceuticals, Rebiotix, ReCor Medical, Regulus Therapeutics, Relief Therapeutics, RenalytixAI, Resverlogix, ReviR Therapeutics, Roche, Roche Diagnostics, Rockwell Medical, Roivant Sciences, Royal Children’s Hospital, Sanguina, Saniona, SanReno Therapeutics, Satellite Healthcare, Scanwell Health, Scohia Pharma, Selecta Biosciences, Selexis, Sequentify, Shanghai Haini Pharmaceutical, Siemens Healthineers, Silence Therapeutics, Singapore General Hospital, SinoMab Bioscience, Sinovant Sciences, Somatus, SOM Biotech, Sonacare Medical, Specialty Renal Products, Spectrum Pharmaceuticals, Spero Therapeutics, Sphingotec, Spruce Biosciences, STADA Arzneimittel, Stanford University, Sumitomo Dainippon Pharma, Sumitomo Pharmaceuticals, Sumitovant Biopharma, Sun Pharmaceutical, Suzhou Sinovent Pharmaceuticals, Swedish Orphan Biovitrum, Swixx Biopharma, SyMap Medical, Takeda Pharmaceutical, Teijin, Telara Pharma, Telix Pharmaceuticals, Terumo Blood and Cell Technologies, Tetra Bio-Pharma, The Medicines Company, Thoeris, Thorne Research, TONIX Pharmaceuticals, toSense, Travere Therapeutics, Trestle Biotherapeutics, Tufts Medical Center, twoXAR, Ubiquigent, Unicycive Therapeutics, Unilife, University of Arkansas, University of Bristol, University of California, San Diego, University of Cambridge, University of Glasgow, University of Houston, University of Miami, University of Pennsylvania, University of Sheffield, University of Texas, University of Texas at El Paso, University of Utah, UpScriptHealth, Ur24Technology, UroGen Pharma, Urotronic, Urovant Sciences, US Army Medical Research Institute of Infectious Diseases, Vanderbilt University, Vaneltix Pharma, Varian Medical Systems, VenatoRx, Vensica Medical, Ventus Therapeutics, Verana Health, Viatris, Vifor-Fresenius Medical Care Renal Pharma, Vifor Pharma, Vinnova, vTv Therapeutics, Weill Cornell Medical College, Winhealth Pharma Group, Wuxi Apptec Laboratory Services, Xisle Pharma Ventures Trust, Xortx Therapeutics, Yeda Research and Development Company, Yonsei University Severance Hospital, Zydus Cadila, ZyVersa Therapeutics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.